Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Dualitas Therapeutics | 2025 | Series A | $65.0M | San Francisco |
| HAYA Therapeutics | 2025 | Grant | Undisclosed | Lausanne |
| Leal Therapeutics | 2025 | Series A | $30.0M | Worcester |
| Harpe Bio | 2025 | Debt Financing | $975K | Raleigh |
| Dispatch Bio | 2025 | Series A | $216.0M | Philadelphia |
| Arialys Therapeutics | 2025 | Series Unknown | $14.8M | La Jolla |
| Hoofprint Biome | 2025 | Series A | $15.0M | Raleigh |
| March Biosciences | 2025 | Grant | $200K | Houston |
| Solu Therapeutics | 2025 | Series A | $41.0M | Boston |
| AIRNA | 2025 | Series B | $155.0M | Cambridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Dualitas Therapeutics | Series A | $65.0M | San Francisco, United States |
| 77 | HAYA Therapeutics | Grant | Undisclosed | Lausanne, Switzerland |
| 78 | Leal Therapeutics | Series A | $30.0M | Worcester, United States |
| 79 | Harpe Bio | Debt Financing | $975K | Raleigh, United States |
| 80 | Dispatch Bio | Series A | $216.0M | Philadelphia, United States |
| 81 | Arialys Therapeutics | Series Unknown | $14.8M | La Jolla, United States |
| 82 | Hoofprint Biome | Series A | $15.0M | Raleigh, United States |
| 83 | March Biosciences | Grant | $200K | Houston, United States |
| 84 | Solu Therapeutics | Series A | $41.0M | Boston, United States |
| 85 | AIRNA | Series B | $155.0M | Cambridge, United States |
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Leal Therapeutics develops novel therapeutics for patients.
Harpe Bio develops sustainable weed control solutions for organic and industrial agriculture.
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
Arialys Therapeutics is a pre-clinical stage company that develops auto-antibody focusing on neuroscience.
Hoofprint Biome is a biotechnology company that develops probiotics that improve the sustainability of ruminant livestock production.
March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.
Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.
AIRNA develops RNA editing technologies to create medicines for various diseases.
Stratus Therapeutics develops off-the-shelf hematopoietic stem cell therapies to treat severe and life-threatening diseases.
Meiogenix is a biotechnology company that develops breeding technologies.
OverT Bio operates as a biotech company that provide cell therapy for cancers.
Autoimmunity BioSolutions develops a future immuno-corrective treatment that restores healthy immune function.
Valora Therapeutics is a biotechnology company that provides engineering of chimeric antibodies .
Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.
Archon Biosciences is a biotechnology firm that promotes next-generation antibody treatments through AI and computational protein design.
Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs).
Judo Bio is a biotechnology company that develops precision therapeutics targeting specific cell populations to address genetic diseases.
858 Therapeutics develops small molecule drugs targeting oncology and immunology.
Red Arrow Therapeutics is a biotech firm that provides systemic cytokine delivery, targeted intratumoral activation, and biological potency.
Radiant is a biotechnology company developing the next generation of multi-specificity.
Molecular Assemblies is developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products.
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Ability Biologics dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need..
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 18 different industry categories.
Among tracked funding rounds, Dispatch Bio received $216.0M in a Series A round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Recent Alexandria Venture Investments portfolio additions include Dualitas Therapeutics, HAYA Therapeutics, Leal Therapeutics, Harpe Bio, Dispatch Bio. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors